We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Please provide feedback for this on the following(scale 1-5, 1 strongly disagree; 5 strongly agree):
* = Mandatory Field
Pulmonary Rehabilitation (PR) is often recommended prior to lung transplantation in patients with end-stage lung disease to improve physiologic performance and surgical outcomes. We caught up with Prof. David R. Nunley (Ohio State University, Columbus, OH, USA) to discuss the aims, design, inclusion criteria and findings from his study analysing the physiological benefits from PR […]
Dupilumab is used to manage chronic rhinosinusitis with nasal polyposis, however there is limited data regarding its use in patients with aspirin-exacerbated respiratory disease (AERD). touchRESPIRATORY caught up with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the aims, eligibility, methodology and findings of his study investigating the real-world outcomes of […]
touchRESPIRATORY were delighted to speak with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the signs and symptoms of aspirin-exacerbated respiratory disease (AERD), the incidence of AERD in people with asthma, the current treatment paradigm for AERD and the unmet needs in its treatment. The abstract ‘Real-world Outcomes of Dupilumab Therapy […]
touchRESPIRATORY were delighted to speak with a valued member of our Editorial Board for touchREVIEWS in Respiratory & Pulmonary Diseases, Dr Ronald Strauss (Case Western Reserve University; Cleveland Allergy and Asthma Center, Cleveland, OH, USA), about the areas in the field of respiratory medicine that he is most looking forward to exploring in 2023. Questions […]
Mepolizumab is a humanized monoclonal antibody used to treat severe eosinophilic asthma. We caught up with Dr Ronald Strauss (Case Western Reserve University; Cleveland Allergy and Asthma Center, Cleveland, OH, USA), a valued member of our Editorial Board for touchREVIEWS in Respiratory & Pulmonary Diseases, to discuss the rationale, findings and clinical significance of his […]
Eosinophilic asthma is a severe subtype of asthma that usually starts in adulthood. It was a pleasure to talk with Dr Ronald Strauss (Case Western Reserve University; Cleveland Allergy and Asthma Center, Cleveland, OH, USA), a valued member of our Editorial Board for touchREVIEWS in Respiratory & Pulmonary Diseases, about the unmet needs in the […]
Dupilumab is indicated as an add-on maintenance treatment in children aged 6 years and older with asthma, and demonstrated clinical efficacy in the pivotal VOYAGE study (NCT0294895). We caught up with Dr Theresa W Guilbert (Cincinnati Children’s Hospital & Medical Center; University of Cincinnati, Cincinnati, OH, USA) to discuss the main findings from a post-hoc […]
touchRESPIRATORY were delighted to speak with Dr Theresa W Guilbert (Cincinnati Children’s Hospital & Medical Center; University of Cincinnati, Cincinnati, OH, USA) about the health and economic burden of asthma exacerbations in children, and the limitations of current therapeutic options for children with asthma. The abstract ‘Impact Of Exacerbation History On Dupilumab Efficacy In Children […]
Tezepelumab is a biologic drug for severe asthma that works by blocking thymic stromal lymphopoietin, a cytokine thought to be involved in airway inflammation. We caught up with Dr Warner Carr (Allergy & Asthma Associates of Southern California, A Medical Group; Southern California Research, Mission Viejo, CA, USA) to discuss the clinical utility of tezepelumab […]
Get the latest clinical insights from touchRESPIRATORY